Waters Corporation’s stock surged 3% premarket to $299 following better-than-expected Q2 results and a transformative billion-dollar acquisition announcement. The analytical instruments specialist reported revenue of $771 million, a 9% year-over-year increase, surpassing forecasts, while adjusted earnings per share rose 12% to $2.95. Recurring revenue grew 11%, with strong performance in pharmaceuticals—particularly in China, where sales jumped 14%—driven by demand for GLP-1 therapies and PFAS testing. The company also revealed plans to acquire BD Biosciences & Diagnostic Solutions, projecting $200 million in cost synergies by year three and $290 million in additional revenue by year five, with immediate EPS accretion.
Raised Guidance Reflects Confidence
Buoyed by robust pharma-sector demand and the BD deal, Waters raised its 2025 outlook, forecasting 5.5%–7.5% constant-currency revenue growth and EPS of $12.95–$13.05, up 10% year-over-year. Q3 EPS is expected at $3.15–$3.25. The acquisition positions Waters to dominate in microbiology and mass spectrometry, tapping into a fast-growing $500 million market. Investors responded positively, signaling renewed faith in the company’s growth trajectory.
